Temozolomide

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献10篇:

客户使用该产品的7个实验数据:

  • D, Scramble (SCR), H82, H865, and H1836 cells were treated with AZD1775 (100 nmol/L) and temozolomide (1 μmol/L) for 24 hours; WEE1 KD cells were treated with just temozolomide (1 μmol/L) for 24 hours. The cells were lysed at 24 hours and subjected to Western blot analysis for phosphorylated WEE1 (pWEE1_S642), pCDC2_Y15 (WEE1 downstream effector), γH2AX (DNA damage marker), PH3 (mitotic marker), cleaved caspase-3 (apoptotic marker), and actin (loading control). E, SCR and WEE1 KD H82, H865, and H1836 cells were treated as described in D and subjected to Western blot analysis for DNA repair markers pATM_S1981, MRE11, RAD51, and E2F1. Actin was used as a loading control.

    Clin Cancer Res, 2017, 23(20):6239-6253. Temozolomide purchased from Selleck.

    C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NHPxfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzR4FOPDhiaB?= MoPYTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN NIS3SpEzPTl4MEK4Ni=>
KellyCis83 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW0PEBp MlzhTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> NWD2WY5UOjV7NkCyPFI>
SK-N-AS NXP4bGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG0PEBp MoTZTWM2OD1{MkeuO|DjiIoEsfMAjVIzNjF3IN88US=> NXP6VHh[OjV7NkCyPFI>
SK-N-ASCis24 NEK4cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7WOFghcA>? NH23ZVBKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? NWnYV|F7OjV7NkCyPFI>
CHP-212 M32yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzCOFghcA>? NG\4b4pKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN MYWyOVk3ODJ6Mh?=
CHP-212Cis100 NFS2THpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LjXVQ5KGh? MmXWTWM2OD17LkW15qCKyrIkgJmwMlg5KM7:TR?= NHnlWXgzPTl4MEK4Ni=>
U87  NFiycYZHfW6ldHnvckBCe3OjeR?= NHXnTnoyODBizszN NWOxZ|ZbOjRvN{KgbC=> NGC0NnhqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= NFzzRVczPThyOEi2PC=>
LN229 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknmNE02OCEQvF2= Ml7kTWM2OD1zNjFOwG0> NXjsc5VlOjV5NUCyO|M>
TR-LN229 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\wdpN4OC13MDFOwG0> M{HOVWlEPTB;N{eg{txO NF;Q[JAzPTd3MEK3Ny=>
U87  NHLye3FCeG:ydH;zbZMhSXO|YYm= MkjvNQKBmzJyMPMAjeK2VQ>? NX\ndWYzOjRiaB?= M4XtO4VvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ MVuyOVY5OTZ4OB?=
U251MG NEPhcVVCeG:ydH;zbZMhSXO|YYm= MXmxNFDDqM7:TR?= M4Hx[FQ5KGh? NFrYS|lRSlN? M4jWfIlv\HWlZYOgZZBweHSxc3nz M2m0SFI2PjhyNE[0
U87MG MlXjRZBweHSxc3nzJGF{e2G7 M2nqclExOMLizszN MX:0PEBp MlfjVGJU M4HpU4lv\HWlZYOgZZBweHSxc3nz MnGwNlU3QDB2NkS=
U87 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTNSpE2OC1|NUCg{txO MlzSOFjDqGkEoB?= NF\iO4FqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NYLmVpZCOjV3NUSyNlM>
U118  NXfSclVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfPdZh5PTBvM{WwJO69VQ>? NXvNWpdNPDkEoHlCpC=> Mn7ibY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> MUCyOVU2PDJ{Mx?=
U87 NWLWW|doTnWwY4Tpc44hSXO|YYm= MXiyOVAwOzVyIN88US=> M1v4SFQ5yqCqwrC= Monn[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm NUHSXIsyOjV3NUSyNlM>
U118  NIjrZ5hHfW6ldHnvckBCe3OjeR?= NUjydVlHOjVyL{O1NEDPxE1? NGTVOYM1QMLiaNMg NFfpUlFmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? M3z1eVI2PTV2MkKz
U87 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILVfpYzPTBxM{WwJO69VQ>? M4LOPFQ5yqCqwrC= M4S0folv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh? NEH3cW8zPTV3NEKyNy=>
A375 NFHGPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILPeZE1QMLiaNMg MlW3TWM2OD1{NkWg{txO Mnu1NlU2OjR3NUK=
A2058 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXizS5A1PDkEoHlCpC=> NIfudYRKSzVyPUGyJO69VQ>? M2\m[|I2PTJ2NUWy
M238 M3LSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrBOFjDqGkEoB?= M1;pPGlEPTB;NECg{txO M4HPZ|I2PTJ2NUWy
M249 NEXv[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:0POKhcMLi MnLNTWM2OD1{NUSg{txO M1O0UVI2PTJ2NUWy
M21 M1zwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q5ZVQ5yqCqwrC= Mn[zTWM2OD1{MkGg{txO NF7kOGMzPTV{NEW1Ni=>
U251 M2[5[2N6fG:2b4jpeJkhSXO|YYm= Ml3lNlAh|ryPwrC= MlHxOFjDqGkEoB?= MlX5doVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NGizWYgzPTR|NEO4NS=>
LN229 NIHoTYVEgXSxdH;4bZR6KEG|c3H5 MnrqNlAh|ryPwrC= NFjhT4Q1QMLiaNMg MWDy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm MYKyOVQ{PDN6MR?=
U373MG-LUC NEToSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nPflczKGh? NWjze5VZUUN3ME62NFAh|ryP NUHpWW5yOjV2M{G5OVM>
U87  M2rkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf1NlUuOjByIN88US=> Ml;yOFjDqGkEoB?= NFPzVnBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYCyOVQxODd2NR?=
U251 M{nzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PLNFI2NTJyMDFOwG0> M1rp[VQ5yqCqwrC= MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHzGO|EzPTRyMEe0OS=>
U251 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PE[FExOC12MECg{txO NEXqVWs4Oi97NjDo MWD0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? M32zN|I2Ozd3Mkex
U373 M3uzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPkNVAxNTRyMDFOwG0> NHnwNFI4Oi97NjDo M2\mT5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MYeyOVM4PTJ5MR?=
U343 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\NclExOC12MECg{txO Mo[zO|IwQTZiaB?= M4C0XJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= M371cFI2Ozd3Mkex
U87MG-luc2 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3CeXIyODBvNECwJO69VQ>? NIS5XXQ4Oi97NjDo NV\DbmtnfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg MWKyOVM4PTJ5MR?=
U87 NEP4W4JHfW6ldHnvckBCe3OjeR?= MmTHNlAxKM7:TR?= M4PhSFQ5KGh? M1P3bYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? NIjofGYzPTN|N{eyNS=>
U251 NVHRdJljTnWwY4Tpc44hSXO|YYm= NWHIemExOjByIN88US=> MnHmOFghcA>? NHroZZVqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w M2TsbFI2OzN5N{Kx
A172 MWnGeY5kfGmxbjDBd5NigQ>? MnjXNlAxKM7:TR?= NVPIclQxPDhiaB?= MWLpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NHfTZmMzPTN|N{eyNS=>
U251 M3zXeWZ2dmO2aX;uJGF{e2G7 NIPMTGQzODBizszN NXnUVm9[PDhiaB?= MmTmbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? NEPlVYIzPTN|N{eyNS=>
A172 MnjMSpVv[3Srb36gRZN{[Xl? M3v2OVIxOCEQvF2= M{DrO|Q5KGh? MnfhbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MViyOVM{Pzd{MR?=
U87 MULGeY5kfGmxbjDBd5NigQ>? NWjnb2ZUOjByIN88US=> NV3ubm5QOjRxN{KvNVIxKGh? MU\pcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MXWyOVM{Pzd{MR?=
U251 NXXyTGFDTnWwY4Tpc44hSXO|YYm= Mmn6NlAxKM7:TR?= MUKyOE84Oi9zMkCgbC=> NXXLbXRJcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NVnIUmFwOjV|M{e3NlE>
A172 NH2xbHVHfW6ldHnvckBCe3OjeR?= NELhTI4zODBizszN MXWyOE84Oi9zMkCgbC=> NYLJe2kxcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MlX0NlU{Ozd5MkG=
SNB19V NXTCc2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHmO{Bl MWHEUXNQ M{WxRmdKPTB;M{WuO:KyOTJizszN NILFWWszPTJ5N{S0NS=>
SNB19M NV;HXGlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvhNlE4KGR? MY\EUXNQ M2XiNGdKPTB;NE[5MlnDuTh6IN88US=> MYGyOVI4PzR2MR?=
SNB19VR MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXy3JIQ> MlnUSG1UVw>? NE\mZYxIUTVyPUK4NE4zyrFzODFOwG0> NIDFdogzPTJ5N{S0NS=>
U373V NHPIVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES0R4o4KGR? MWfEUXNQ NV7oTYJ4T0l3ME22PE4xyrF|MjFOwG0> NWDYelRwOjV{N{e0OFE>
U373M NXnPOWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rSd|ch\A>? MV7EUXNQ MWjHTVUxRTN4OD63xtE5PiEQvF2= MofpNlUzPzd2NEG=
U373VR M164fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzpW2t7PyCm MXPEUXNQ MXXHTVUxRTJ6OD64xtE{OyEQvF2= NWHxXmJ{OjV{N{e0OFE>
U87MG Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC3O{Bl NGjweItFVVOR M{XZZmdKPTB;M{iuN:KyOjBizszN NWe1enFROjV{N{e0OFE>
HCT116 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwdVch\A>? Mn7TSG1UVw>? MVXHTVUxRTV5OT65xtE{OiEQvF2= NV:wV5dpOjV{N{e0OFE>
DLD1 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4NFMyPyCm M{mzOGROW09? NITx[mpIUTVyPUWwNU41yrF7MzFOwG0> NF;Je3MzPTJ5N{S0NS=>
MRC5 NFS2O4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rmOVch\A>? MorMSG1UVw>? NI\EdndIUTVyPUS0PU41yrF6IN88US=> MoLpNlUzPzd2NEG=
SNB19V  Mny4SpVv[3Srb36gRZN{[Xl? MV:xNFAh|ryPwrDUUXo> MWOwMVczKGh? MoXCbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> M33J[|I2Ojd5NESx
T98G  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqyTpdRPS9zMD:xOUDPxE1? M33zSlI1yqCq M{LifIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU MmTaNlUzPjJ7NkG=
U251  Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDyOU8yOC9zNTFOwG0> MUiyOOKhcA>? Ml7QbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= NIrrPXkzPTJ4Mkm2NS=>
T98G  Mn;FSpVv[3Srb36gRZN{[Xl? M4HhUlE2KM7:TR?= Mo\jNlTDqGh? M3\idolv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= NVzDemV2OjV{NkK5OlE>
U251  M{PVUWZ2dmO2aX;uJGF{e2G7 M1PSVlE2KM7:TR?= NEHVXGYzPMLiaB?= MkfvbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MY[yOVI3Ojl4MR?=
U-87 MG M3vzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0NFczKGh? NX\NN5drUUN3ME2wMlk{KG2PwrC= MWKyOVI1PTN|Mh?=
U-118 MG M1HWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi0cGs4OiCq M4G5TGlEPTB;MT6wOUBuVcLi MX6yOVI1PTN|Mh?=
U87 NIS2cXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDyWYszPCCq M3zsbWlEPTB;Mk[wMlM1KM7:TdMg NHnXR|czPTF5M{KzNy=>
U87 GSLCs NVvNVHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGyOEBp MW\JR|UxRTd4Nj6xNUDPxE4EoB?= NFXLcVczPTF5M{KzNy=>
U87MG NX\ZemFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp MmroTWM2OD1zNT62NlUh|ryPwrC= MXOyOVA2ODlzNR?=
U251 NWTE[HNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHKNVAxNTRyMDFOwG0> MVK0PEBp NIO5THVFVVOR NYLBUnRbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVzBTHpQOjR4MkO3N|Y>
U87 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[2dlExOC12MECg{txO MXS0PEBp MlPVSG1UVw>? Ml[5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEfYXYozPDZ{M{ezOi=>
MDA-MB-231-br NF;rWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMVExKM7:TR?= NX\CU3FtPDhiaB?= NXfYdmdkTE2VTx?= MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NG\1Nm8zPDZ{M{ezOi=>
HCC-1937 NXPEWW9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEZmMxNTNyMDFOwG0> MkPBOFghcA>? NHrFUVFFVVOR MkfabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{X0b|I1PjJ|N{O2
MDA-MB-231 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPk[I9OOC12MDFOwG0> MlSzOFghcA>? MUPEUXNQ MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX\SfY1qOjR4MkO3N|Y>
MDA-MB-468 NEHtb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMVUxOCEQvF2= NXfNeGp5PDhiaB?= MojOSG1UVw>? M3vWSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVHD[HJROjR4MkO3N|Y>
T47D NXv2dIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDCNE0yODBizszN NHKzOI81QCCq M4HY[2ROW09? Moe3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmDKNlQ3OjN5M{[=
MCF7 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDMcJMxNTFyMECg{txO M3nFO|Q5KGh? M2jUOmROW09? M2\wVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3:xTVI1PjJ|N{O2
Hs683 NYXVbWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDpNE0yODByIN88US=> NFLERY46PiCq MV7JR|UxRTF{OD65JO69VQ>? MnvvNlQ1QTV7MEe=
U87 NGXkN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiwMVExODBizszN MnzFPVYhcA>? MmLwTWM2OD1zOD60OUDPxE1? NXXQU3N4OjR2OUW5NFc>
LNZ308 NXK3R|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn5eVExNTFyMECg{txO NHTlWIk6PiCq NXK3ZYppUUN3ME2zNlYvPyEQvF2= MVWyOFQ6PTlyNx?=
U87 MVfBdI9xfG:|aYOgRZN{[Xl? NHTvenoyODBizszN NW\uU|V[PDhiaB?= NITaZ3hFVVOR NYTYOJZLcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NUjPc|UzOjR2OEG1PFY>
U251  M2O4eGFxd3C2b4Ppd{BCe3OjeR?= NVO1boxiOTByIN88US=> MlnjOFghcA>? M4DKVWROW09? NHHpNolqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 M{[xWlI1PDhzNUi2
U251 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzjNlQhcA>? M1zj[GlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN M2PhdlI1OzJ4OUW0
U251 NXnQTG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LuOlQ5KGh? MkPITWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= MV[yOFMzPjl3NB?=
U251 NGj4ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrsZ4Q4OiCq NFnwR5VKSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=> M{LqclI1OzJ4OUW0
U251 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkezPVYhcA>? MWDJR|UxRTZ7Lkiy5qCKyrIkgJmzMlA1KM7:TR?= MWeyOFMzPjl3NB?=
T98G NWHJUJdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Hhe|AuPzVyIN88US=> NEfEfnk4Oi97NjDo M2nKNolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWWyOFMzPDB6MB?=
U251-MG NUnmfmhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnZbmtkOC16MECg{txO NEG5U3M4OiCq Mk\kbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4\nXFI1ODl|NkOw
D54-MG M{jCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S1RlAuQDByIN88US=> NF\rZ4E4OiCq MUTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUmyOFA6OzZ|MB?=
SHG-44 NUDUR4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe4NoUyOC1{MECg{txO MXi5OkBp MmCxTWM2OD17LkezJOKyKDJwMUKg{txO M{\VblI1ODZ3NU[5
U373  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfqNVAuOjByIN88US=> MlTsPVYhcA>? NX3mbmRXUUN3ME2xNE4yOyEEsTCxMlAzKM7:TR?= NWjX[44xOjRyNkW1Olk>
HT-29  NGO0TXdHfW6ldHnvckBCe3OjeR?= MkXuOVAxKM7:TR?= NULGb41vOjRxNEigbC=> MlrW[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NF22N3AzPDB|OEC2PC=>
PC-3  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUewMVI2KM7:TR?= NFrTO4c1QCCq M17aSIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>? MmW4NlM4PDZ7M{S=
PC-3  NYDLNnpCSXCxcITvd4l{KEG|c3H5 MnXJNlUh|ryP M4H4W|Q5KGh? NHjw[2NqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NUHIXlJOOjN5NE[5N|Q>
T98G MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi1NE01ODBizszN MWGxOFQhcA>? NHWzXmVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkXVNlM4OTV2OUm=
U87-MG M4rJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO2[5IyODBiwsXN M3;NfFczKGh? MVzpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD NXfDTpg1OjN4OU[3PFg>
U251-MG MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33rdFExOCEEtV2= MYW3NkBp M3vNVYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NUXaTYNmOjN4OU[3PFg>
LNT-229 NIjQOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT5OnNKOy1zMECg{txO MkjzNlQhcA>? NVzmc|FYcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVqyN|Y3PzZ|Mh?=
T98G M{jmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qSlExNTdyMDFOwG0> NVO3W5lIOjRiaB?= M{\MSYlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml;LNlM3Pjd4M{K=
U87  M1fKV2Z2dmO2aX;uJGF{e2G7 NYi2U|NyOTByINM1US=> NWS5XodDOyCq MkXx[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> NXXzemtPOjN4Nke0Olk>
HCT116 MUjGeY5kfGmxbjDBd5NigQ>? NGHHZWgyODBiwsXN NYnnPWo4OyCq NIfTV4hqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MlHoNlM3Pjd2Nkm=
HCT3-6 NUj3PYxzTnWwY4Tpc44hSXO|YYm= M2Pn[VExOCEEtV2= NVTiOZNVOyCq NUPrXpJCcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= MmfJNlM3Pjd2Nkm=
U-87  NGT0UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMVQxKM7:TR?= NWDqVYRqOTJiZB?= M33oS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4fpfVI{PjR3N{K5
U-87  MUDBdI9xfG:|aYOgRZN{[Xl? MW[wMVQxKM7:TR?= NV7UW4F3Oy94IHS= M363NYlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MX:yN|Y1PTd{OR?=
U-87  MmLYSpVv[3Srb36gRZN{[Xl? M{\jNFAuPDBizszN M3\LNlMwPiCm NHi3bYtqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NWLtS2ZFOjN4NEW3Nlk>
GB-SCC010 NF:3O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy0JIQ> NXjSe3pPUUN3ME2yNlYh|ryP NVjVTpE{OjN4MUK3OVU>
GB-SCC026 M3S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHBcZY1KGR? Mor1TWM2OD13Mz6xJO69VQ>? MoXkNlM3OTJ5NUW=
GB-SCC028 NWLVUZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq0JIQ> MVfJR|UxRTF4NzFOwG0> NHLEWYkzOzZzMke1OS=>
U87 M3LpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPN3U1KGR? M{HESGlEPTB;NEWuNkDPxE1? NWLJN45GOjN4MUK3OVU>
U87 stem cell MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G3W|Qh\A>? MYPJR|UxRTZ4Lkeg{txO MX[yN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
稳定性 powder
in solvent
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID